TOI vs. PTWO, SHLT, ACXP, INAB, OCUP, IRIX, OPGN, LFWD, BCLI, and GANX
Should you be buying Oncology Institute stock or one of its competitors? The main competitors of Oncology Institute include Pono Capital Two (PTWO), SHL Telemedicine (SHLT), Acurx Pharmaceuticals (ACXP), IN8bio (INAB), Ocuphire Pharma (OCUP), IRIDEX (IRIX), OpGen (OPGN), ReWalk Robotics (LFWD), Brainstorm Cell Therapeutics (BCLI), and Gain Therapeutics (GANX). These companies are all part of the "medical" sector.
Pono Capital Two (NASDAQ:PTWO) and Oncology Institute (NASDAQ:TOI) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their community ranking, analyst recommendations, earnings, risk, valuation, profitability, media sentiment, institutional ownership and dividends.
Pono Capital Two has a beta of 0.01, suggesting that its share price is 99% less volatile than the S&P 500. Comparatively, Oncology Institute has a beta of 0.82, suggesting that its share price is 18% less volatile than the S&P 500.
60.8% of Pono Capital Two shares are owned by institutional investors. Comparatively, 36.9% of Oncology Institute shares are owned by institutional investors. 63.9% of Pono Capital Two shares are owned by insiders. Comparatively, 9.5% of Oncology Institute shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
In the previous week, Oncology Institute had 4 more articles in the media than Pono Capital Two. MarketBeat recorded 5 mentions for Oncology Institute and 1 mentions for Pono Capital Two. Oncology Institute's average media sentiment score of -0.36 beat Pono Capital Two's score of -0.79 indicating that Pono Capital Two is being referred to more favorably in the media.
Oncology Institute received 4 more outperform votes than Pono Capital Two when rated by MarketBeat users.
Pono Capital Two has a net margin of 0.00% compared to Pono Capital Two's net margin of -20.28%. Oncology Institute's return on equity of -6.63% beat Pono Capital Two's return on equity.
Oncology Institute has a consensus price target of $2.25, suggesting a potential upside of 309.91%. Given Pono Capital Two's higher probable upside, analysts plainly believe Oncology Institute is more favorable than Pono Capital Two.
Pono Capital Two has higher earnings, but lower revenue than Oncology Institute.
Summary
Pono Capital Two beats Oncology Institute on 7 of the 13 factors compared between the two stocks.
Get Oncology Institute News Delivered to You Automatically
Sign up to receive the latest news and ratings for TOI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TOI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Oncology Institute Competitors List
Related Companies and Tools
